• FDA grants regular approval to Keytruda-Lenvima combination for endometrial carcinoma

    6 days ago - By Healio

    The FDA granted regular approval to the combination of pembrolizumab and lenvatinib for certain women with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.
    The approval applies to use of the agent by women whose disease progressed after systemic therapy in any setting and who are not candidates for curative surgery or radiation.
    The agency had granted accelerated approval to the combination for this indication in September 2019. Continued approval was contingent upon verification and description of clinical benefit.
    The FDA based the
    Read more ...

     

  • FDA Fully Approves Combination for Advanced Endometrial Cancer

    FDA Fully Approves Combination for Advanced Endometrial Cancer

    6 days ago - By Medscape

    Pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma is now fully approved.
    FDA Approvals
    Read more ...